The metabolic syndrome and cardiovascular disease

References

• Kylin E. Studien ueber das Hypertonie‐Hyperglykamie‐Hyperurikamiesyndrom. Zentralblatt fuer Innere Medizin 1923; 44: 105–27
   Google Scholar
• Vague J. La differenciation sexuelle, factor determinants des formes de l'obesite. Press Med 1947; 30: 339–40
   Google Scholar
• Avogaro P., Crepaldi G., Enzi G., Tiengo A. Associazione di iperlipemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 1967; 4: 572–90
   Google Scholar
• Reaven G. M. Banting lecture. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607
   PubMed Web of Science ®Google Scholar
• IDF Consensus. The IDF Consensus worldwide definition of the Metabolic Syndrome. http://www.idf.org./home/index.cfm?node = 1388
   Google Scholar
• WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization, GenevaSwitzerland 1999, Publication WHO/NCD/NCS/99.2
   Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97
   PubMed Web of Science ®Google Scholar
• DeFronzo R. A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94
   PubMed Web of Science ®Google Scholar
• Kaplan N. M. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–20
   PubMed Web of Science ®Google Scholar
• Modan M., Halkin H., Almong S., Lusky A., Eshkol A., Shefi M., et al. Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809–17
   PubMed Web of Science ®Google Scholar
• Hjiermann I. The Metabolic Cardiovascular Syndrome: Syndrome X, Reaven's Syndrome, Insulin Resistance Syndrome, and Atherothrombotic Syndrome. J Cardiovasc Pharmacol 1992; 20((suppl 8))S5–10
   Google Scholar
• Zimmet P. Z. Hyperinsulinemia. How innocent a bystander?. Diabetes Care 1993; 16((suppl 3))56–70
   Google Scholar
• Bonora E., Kiechl S., Oberhollenzer F., Egger G., Bonadonna R. C., Muggeo M. Impaired glucose tolerance, type 2 diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia 2000; 43: 156–64
   Google Scholar
• Willeit J., Kiechl S., Oberhollenzer F., Rungger G., Egger G., Bonora E., et al. Distinct risk profiles of early and advanced atherosclerosis. Prospective results from the Bruneck Study. Arterioscl Thromb Vasc Biol 2000; 20: 529–37
   PubMedGoogle Scholar
• Kannel W. B., McGee D. L. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035–8
   PubMed Web of Science ®Google Scholar
• Stamler J., Vaccaro O., Neaton J. D., Wentworth D., for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12‐yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44
   PubMed Web of Science ®Google Scholar
• Manson J. E., Colditz G. A., Stampfer M. J., Willet W. C., Krolewski A. S., Rosner B., et al. A prospective study of maturity‐onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141–7
   PubMed Web of Science ®Google Scholar
• Kleinman J. C., Donahue R. P., Harris M. I., Finucane F. F., Madans J. H., Brock D. B. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128: 389–401
   PubMed Web of Science ®Google Scholar
• Wei M., Gaskill S. P., Haffner S. M., Stern M. P. Effects of diabetes and the level of glycemia on all‐cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21: 1167–72
   PubMed Web of Science ®Google Scholar
• Kuller L. H., Velentgas P., Barzilay J., Beauchamp N. J., O'Leary D. H., Savage P. J. Diabetes mellitus, subclinical cardiovascular disease and risk of incident cardiovascular disease and all‐cause mortality. Arterioscl Thromb Vasc Biol 2000; 20: 823–9
   PubMed Web of Science ®Google Scholar
• Miettinen H., Lehto S., Salomaa V., Mahonen M., Niemela M., Haffner S. M., , for the FINMONICA Myocardial Infarction Register Study Group, et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21: 69–75
   PubMed Web of Science ®Google Scholar
• Olsson T., Viitanen M., Asplund K., Eriksson S., Hagg E. Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia 1990; 33: 244–9
   Google Scholar
• Gu K., Cowie C. C., Harris M. I. Mortality in adults with and without diabetes in a national cohort of the U.S. population,. 1971–1993. Diabetes Care 1998; 21: 1138–45
   PubMed Web of Science ®Google Scholar
• De Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause‐specific mortality in type 2 diabetes. Diabetes Care 1999; 22: 756–61
   PubMed Web of Science ®Google Scholar
• The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2‐h diagnostic criteria. Arch Intern Med 2001; 161: 397–404
   PubMed Web of Science ®Google Scholar
• Khaw K. T., Wareham N., Luben R., Bingham S., Oakes S., Welch A., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC‐Norfolk). BMJ 2001; 322: 15–8
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53
   PubMed Web of Science ®Google Scholar
• Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow‐up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care 2003; 26: 3160–7
   Google Scholar
• Kannel W. B., LeBauer E. J., Dawber T. R., McNamara P. M. Relation of body weight to development of coronary heart disease: The Framingham Study. Circulation 1967; 35: 734–44
   PubMed Web of Science ®Google Scholar
• Harris T. B., Ballard‐Barbash R., Madans J., Makuc D. M., Feldman J. J. Overweight, weight loss, and risk of coronary heart disease in older women: the NHANES I Epidemiologic Follow‐up Study. Am J Epidemiol 1993; 12: 1318–27
   Google Scholar
• Knowler W. C., Pettitt D. J., Savage P. J., Bennett P. H. Diabetes incidence in Pima Indians: contribution of obesity and parental diabetes. Am J Epidemiol 1981; 113: 144–51
   PubMed Web of Science ®Google Scholar
• Garrison R. J., Wilson P. W. F., Castelli W. P., Feinleib M., Kannel W. B., McNamara P. M. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism 1980; 29: 1053–60
   PubMed Web of Science ®Google Scholar
• Stamler R., Stamler J., Reidlinger W. F., Algera G., Roberts R. H. Weight and blood pressure: findings in hypertension screening of 1 milion Americans. JAMA 1978; 240: 1607–10
   PubMed Web of Science ®Google Scholar
• Huber H. B., Feinleib M., McNamara P. M., Castelli W. P. Obesity as an independent risk factor for cardiovascular disease: A 26‐year follow‐up of participants in the Framingham Heart Study. Circulation 1983; 67: 968–77
   Google Scholar
• Manson J. E., Colditz G. A., Stampfer M. J., Willett W. C., Rosner B., Momson R. R., et al. A prospective study of obesity and risk of coronary hearth disease in women. N Engl J Med 1990; 322: 882–9
   PubMed Web of Science ®Google Scholar
• Larsson B., Svardsudd K., Welin L., Wilhelmsen L., Bjorntorp P., Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in. 1913. BMJ 1984; 288: 1401–4
   PubMed Web of Science ®Google Scholar
• Lapidus L., Bengsston C., Larsson B., Pennert K., Rybo E., Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12‐year follow up of participants in the population study of women in Gotheburg, Sweden. BMJ 1984; 289: 1257–61
   PubMed Web of Science ®Google Scholar
• Ohlson L. O., Larsson B., Svardsudd K., Welin L., Eriksson H., Wilhelmsen L., et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow‐up of the participants in the Study of Men Born in. 1913. Diabetes 1985; 34: 1055–8
   PubMed Web of Science ®Google Scholar
• Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14: 1132–43
   PubMed Web of Science ®Google Scholar
• Grundy S. M., Benjamin I. J., Burke G. L., Chait A., Eckel R. H., Howard B. V., et al. Diabetes and cardiovascular disease. A statement for the Healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134–46
   PubMed Web of Science ®Google Scholar
• Bonora E., Zenere M., Branzi P., Bagnani M., Maggiulli L., Tosi F., et al. Influence of body fat and its regional localization on risk factors for atherosclerosis in young men. Am J Epidemiol 1992; 135: 1271–8
   Google Scholar
• Pouliot M. C., Despres J. P., Lemieux S., Moorjani S., Bouchard C., Tremblay A., et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460–8
   PubMed Web of Science ®Google Scholar
• Bonora E., Del Prato S., Bonadonna R., Gulli G., Solini A., Shank M., et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 1992; 41: 1151–9
   Google Scholar
• Bonora E. Relationship between regional fat distribution and insulin resistance. Int J Obes 2000; 24((suppl. 2))S32–5
   Google Scholar
• Seidell J. C., Oosterlee A., Thijssen M. A. O., Burema J., Deurenberg P., Hautvast J. G. A. J., et al. Assessment of intra‐abdominal and subcutaneous abdominal fat: Relation between anthropometry and computed tomography. Am J Clin Nutr 1987; 45: 7–13
   PubMedGoogle Scholar
• Bonora E., Micciolo R., Ghiatas A. A., Lancaster J. L., Alyassin A., Muggeo M., et al. Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal tissue from simple anthropometric measurements?. Metabolism 1995; 44: 1617–25
   PubMed Web of Science ®Google Scholar
• Boyko E. J., Fujimoto W. Y., Leonetti D. L., Newell‐Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000; 23: 465–71
   PubMed Web of Science ®Google Scholar
• Fujimoto W. Y., Bergstrom R. W., Boyko E. J., Chen K. W., Leonetti D., Newell‐Morris L., et al. Visceral adiposity and incident coronary heart disease in Japanese‐American men. Diabetes Care 1999; 1808–12
   Google Scholar
• Hokanson J. E., Austin M. A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high‐density lipoprotein cholesterol level: a meta‐analysis of population‐based prospective studies. J Cardiovasc Risk 1996; 3: 213–9
   PubMedGoogle Scholar
• Gotto A. M., Jr. Triglyceride: the forgotten risk factor. Circulation 1998; 97: 1027–8
   PubMed Web of Science ®Google Scholar
• Miller M., Seidler A., Moalemi A., Pearson T. A. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long‐Term Study. J Am Coll Cardiol 1998; 31: 1252–7
   PubMed Web of Science ®Google Scholar
• Tanne D., Koren‐Morag N., Graff E., Goldbourt U. Blood lipids and first‐ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001; 104: 2892–7
   PubMed Web of Science ®Google Scholar
• Assmann G., Schulte H. Relation of high‐density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733–7
   PubMed Web of Science ®Google Scholar
• Brunzell J. D., Ayyobi A. F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003; 115((Suppl 8A))24S–8
   Google Scholar
• Halle M., Berg A., Baumstark M. W., Konig D., Huonker M., Keul J. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels. Atherosclerosis 1999; 143: 185–92
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• Murakami T., Michelagnoli S., Longhi R., Gianfranceschi G., Pazzucconi F., Calabresi L. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995; 15: 1819–28
   PubMed Web of Science ®Google Scholar
• Castelli W. P., Garrison R. J., Wilson P. W. F., Abbott R. D., Kalousdian S., Kannel W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835–8
   PubMed Web of Science ®Google Scholar
• Jacobs D. R., Jr, Mebane I. L., Bangdiwala S. I., Criqui M. H., Tyroler H. A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow‐up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32–47
   PubMed Web of Science ®Google Scholar
• Stampfer M. J., Sacks F. M., Salvini S., Willett W. C., Hennekens C. H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373–81
   PubMed Web of Science ®Google Scholar
• Bonora E., Targher G., Branzi P., Zenere M., Saggiani F., Zenti M. G., et al. Cardiovascular risk profile in 38‐yr and 18‐yr‐old men. Contribution of body fat content and regional fat distribution. Int J Obes 1996; 20: 28–36
   Google Scholar
• Bonora E., Willeit J., Kiechl S., Oberhollenzer F., Egger G., Bonadonna R. C., et al. U‐shaped and J‐shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care 1998; 21: 221–30
   Google Scholar
• Lewis G. F., Rader D. J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221–32
   PubMed Web of Science ®Google Scholar
• Navab M., Ananthramaiah G. M., Reddy S. T., Van Lenten B. J., Ansell B. J., Hama S., et al. The double jeopardy of HDL. Ann Med 2005; 37: 173–8
   PubMed Web of Science ®Google Scholar
• Kannel W. B., Gordon T., Schwartz M. J. Systolic vs. diastolic blood pressure and risk of coronary artery disease. The Framingham Study. Am J Med 1971; 27: 335–46
   Google Scholar
• Rutan G. H., Kuller L. H., Neaton J. D., Wentworth D. N., McDonald R. H., Smith W. M. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 1988; 77: 504–14
   PubMed Web of Science ®Google Scholar
• O'Donnell C. J., Kannel W. B. Cardiovascular risks of hypertension: lessons from observational studies. J Hypertens 1998; 16((suppl 1))S3–7
   Google Scholar
• He J., Whelton P. K. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138((3 Pt 2))211–9
   Google Scholar
• Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., , on behalf of the INTERHEART Study Investigators, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case‐control study. Lancet 2004; 364: 937–52
   PubMed Web of Science ®Google Scholar
• Vasan R. S., Larson M. G., Leip E. P., Evans J. C., O'Donnell C. J., Kannel W. B., et al. Impact of high‐normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–7
   PubMed Web of Science ®Google Scholar
• Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–52
   PubMed Web of Science ®Google Scholar
• Panza J. A., Quyyumi A. A., Brush J. E., Jr, Epstein S. E. Abnormal endothelium‐dependent relaxation in patients with essential hypertension. N Engl J Med 1900; 323: 22–7
   Google Scholar
• Brunner H., Cockcroft J. R., Deanfield J., Donald A., Ferrannini E., Halcox J., et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233–46
   PubMed Web of Science ®Google Scholar
• Halcox J. P., Schenke W. H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M. A. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653–8
   PubMed Web of Science ®Google Scholar
• Targonski P. V., Bonetti P. O., Pumper G. M., Higano S. T., Holmes D. R., Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003; 107: 2805–9
   PubMed Web of Science ®Google Scholar
• Viberti G. Etiology and prognostic significance of albuminuria in diabetes. Diabetes Care 1988; 11: 840–5
   PubMedGoogle Scholar
• Stehouwer C. D. A., Gall M. A., Twisk J. W. R., Knudsen E., Emeis J. J., Parving H. H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low‐grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157–65
   PubMed Web of Science ®Google Scholar
• Valmadrid C. T., Klein R., Moss S. E., Klein B. E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older‐onset diabetes mellitus. Arch Intern Med 2000; 160: 1093–100
   PubMed Web of Science ®Google Scholar
• Borch‐Johnsen K., Feldt‐Rasmussen, Strandgaard S., Schroll M., Jensen J. S. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992–7
   PubMed Web of Science ®Google Scholar
• Klausen K., Borch‐Johnsen K., Feldt‐Rasmussen B., Jensen G., Clausen P., Scharling H., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32–5
   PubMed Web of Science ®Google Scholar
• Del Prato S., Bonadonna R. C., Bonora E., Gulli G., Solini A., Shank M., et al. Characterization of cellular defects of insulin action in type II (non‐insulin‐dependent) diabetes mellitus. J Clin Invest 1993; 91: 484–94
   Google Scholar
• Bonora E., Bonadonna R. C., Del Prato S., Gulli G., Solini A., Matsuda M., et al. In vivo glucose metabolism in obese and type II diabetic subjects with and without hypertension. Diabetes 1993; 42: 764–72
   PubMed Web of Science ®Google Scholar
• Bonora E., Targher G., Alberiche M., Formentini G., Calcaterra F., Marini F., et al. Predictors of insulin sensitivity in type 2 diabetes mellitus. Diabetic Med 2002; 19: 535–42
   PubMed Web of Science ®Google Scholar
• Bonora E., Targher G., Alberiche M., Bonadonna R. C., Zenere M. B., Saggiani F., et al. Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 2073–9
   Google Scholar
• Zavaroni I., Bonora E., Pagliara M., Dall'Aglio E., Luchetti L., Buonanno G., et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 703–6
   Google Scholar
• Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., et al. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes 1998; 47: 1643–9
   PubMed Web of Science ®Google Scholar
• Laakso M., Sarlund H., Salonen R., Suhonen M., Pyorala K., Salonen J. T., et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991; 11: 1068–76
   PubMed Web of Science ®Google Scholar
• Inchiostro S., Bertoli G., Zanette G., Donadon V. Evidence of higher insulin resistance in NIDDM patients with ischaemic heart disease. Diabetologia 1994; 37: 597–603
   Google Scholar
• Bressler P., Bailey S. R., Matsuda M., DeFronzo R. A. Insulin resistance and coronary heart disease. Diabetologia 1996; 39: 1345–50
   PubMed Web of Science ®Google Scholar
• Howard G., O'Leary D. H., Zaccaro D., Haffner S., Rewers M., Hamman R., et al. and the Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809–17
   PubMed Web of Science ®Google Scholar
• Bonora E., Tessari R., Micciolo R., Zenere M., Targher G., Padovani R., et al. Intimal‐medial thickness of the carotid artery in nondiabetic and non‐insulin‐dependent diabetic subjects. Relationship with insulin resistance. Diabetes Care 1997; 20: 627–31
   Google Scholar
• Hanley A. J. G., Williams K., Stern M. P., Haffner S. M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002; 25: 1177–84
   PubMed Web of Science ®Google Scholar
• Hedblad B., Nilsson P., Engstrom G., Berglund G., Janzon L. Insulin resistance in non‐diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002; 19: 470–5
   PubMed Web of Science ®Google Scholar
• Robins S. J., Bloomfield Rubins H., Faas F. H., Schaefer E. J., Elam M. B., et al. on behalf of the VA‐HIT Study Group. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veteran Affairs HDL Intervention Trial (VA‐HIT). Diabetes Care 2003; 26: 1513–7
   PubMed Web of Science ®Google Scholar
• Bonora E., Targher G., Alberiche M., Bonadonna R. C., Saggiani F., Zenere M. B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degree of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57–63
   PubMed Web of Science ®Google Scholar
• Bonora E., Formentini G., Calcaterra F., Lombardi S., Marini F., Zenari L., et al. HOMA‐estimated insulin resistance is a independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135–41
   PubMed Web of Science ®Google Scholar
• Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R., et al. The Metabolic Syndrome: epidemiology and more extensive phenotypic description. Cross‐sectional data from the Bruneck Study. Int J Obes 2003; 27: 1283–9
   PubMed Web of Science ®Google Scholar
• Toft I., Bonaa K. A., Ingebretsen O. C., Nordoy A., Birkeland K. I., Jenssen T. Gender differences in the relationships between plasma plasminogen activator inhibitor‐1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol 1997; 17: 553–9
   Google Scholar
• Imperatore G., Riccardi G., Iovine C., Rivellese A. A., Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998; 21: 649–54
   Google Scholar
• Wannamethee S. G., Lowe G. D. O., Shaper A. G., Rumley A., Lennon L., Whincup P. H. Insulin resistance, hemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease. Diabetologia 2004; 47: 1557–65
   PubMed Web of Science ®Google Scholar
• Yudkin J. S., Stehouwer J. J., Emeis J. J., Coppack S. W. C‐reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19: 972–8
   PubMed Web of Science ®Google Scholar
• Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Almeras N., et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 2000; 102: 179–84
   PubMed Web of Science ®Google Scholar
• Holvoet P., Kritchevsky S. B., Tracy R. P., Mertens A., Rubin S. M., Butler J., et al. The Metabolic Syndrome, circulating oxidized LDL, and risk of myocardial infarction in a well functioning elderly people in the Health, Aging and Body Compostion Cohort. Diabetes 2004; 53: 1068–73
   PubMed Web of Science ®Google Scholar
• Byrne C. D., Maison P., Halsall D., Martensz N., Hales C. N., Wareham N. J. Cross‐sectional but not longitudinal associations between non‐esterified fatty acid levels and glucose intolerance and other features of the Metabolic Syndrome. Diabet Med 1999; 16: 1007–15
   Google Scholar
• Schmidt M. I., Watson R. L., Duncan B. B., Metcalf P., Brancati F. L., Sharret A. R., , for the Atherosclerosis Risk in Community Study Investigators, et al. Clustering of dyslipidemia, hypeuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in the general population. Metabolism 1996; 45: 699–706
   PubMed Web of Science ®Google Scholar
• Festa A., D'Agostino R., Jr, Howard G., Mykkanen L., Tracy R. P., Haffner S. M. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–7
   PubMed Web of Science ®Google Scholar
• Mendall M. A., Patel P., Ballam L., Strachan D., Northfield T. C. C‐reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061–5
   PubMed Web of Science ®Google Scholar
• Pickup J. C., Mattock M. B., Chusney G. D., Burt D. NIDDM as a disease of the innate immune system: association of acute‐phase reactants and interleukin‐6 with metabolic syndrome X. Diabetologia 1997; 40: 1286–92
   PubMed Web of Science ®Google Scholar
• Fernandez‐Real J. M., Ricart‐Engel W., Arroyo E., Balanca R., Casamitjana‐Abella R., Cabrero D., et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 62–8
   PubMed Web of Science ®Google Scholar
• Hak A. E., Pols H. A., Stehouwer C. D., Mejer J., Kiliaan A. J., Hofman A., et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam Study. J Clin Endocrinol Metab 2001; 86: 4398–405
   PubMed Web of Science ®Google Scholar
• Meigs J. B., Jacques P. F., Selhub J., Singer D. E., Nathan D. M., Rifai N., et al. Fasting plasma homocystein levels in the Insulin Resistance Syndrome. Diabetes Care 2001; 24: 1403–10
   PubMed Web of Science ®Google Scholar
• Leyva F., Godsland I. F., Ghatei M., Proudler A. J., Aldis S., Walton C., et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998; 18: 928–33
   PubMed Web of Science ®Google Scholar
• Wallenfeldt K., Bokemark L., Wikstrand J., Hulthe J., Fagerberg B. Apolipoprotein B/apolipoprotein A‐I in relation to the metabolic syndrome and change in carotid artery intima‐media thickness during 3 years in middle‐aged men. Stroke 2004; 35: 2248–52
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and the Metabolic Syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29–33
   PubMed Web of Science ®Google Scholar
• Nagi D. K., Tracy R., Pratley R. Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor‐1 in Pima Indians. Metabolism 1996; 45: 1243–7
   PubMed Web of Science ®Google Scholar
• Festa A., D'Agostino R., jr, Mykkanen L., Tracy R. P., Zaccaro D. J., Hales C. N., et al. Relative contribution of insulin and its precursors to fibrinogen and PAI‐1 in a large population with different states of of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562–8
   PubMed Web of Science ®Google Scholar
• Vuorinen‐Markkola H., Yki‐Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994; 78: 25–9
   PubMed Web of Science ®Google Scholar
• Temelkova‐Kurktschiev T., Siegert G., Bergmann S., Henkel E., Koehler C., Jaross W., et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743–9
   PubMed Web of Science ®Google Scholar
• Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R. E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulienemia. J Clin Endocrinol Metab 2001; 86: 1930–5
   PubMed Web of Science ®Google Scholar
• Donahue R. P., Prineas R. J., Donahue R. D., Zimmet P., Bean J. A., De Courten M., et al. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care 1999; 22: 1092–6
   Web of Science ®Google Scholar
• Falk E., Shah P. K., Fuster V. Pathogenesis of plaque dysruption. Atherosclerosis and coronary artery disease., V Fuster, R Ross, E. J Topol, editors. Lippincott‐Raven, Philadelphia 1996; Vol. 2: p 492–510, In
   Google Scholar
• Wilhelmsen L., Svärdsudd K., Korsan‐Bengtsen K., Larsson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501–5
   PubMed Web of Science ®Google Scholar
• Kannel W. B., Wolf P. A., Castelli W. P., D'Agostino R. B. Fibrinogen and risk of cardiovascolar disease. The Framingham Study. JAMA 1987; 258: 1183–6
   PubMed Web of Science ®Google Scholar
• Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C‐reactive protein, albumin, or leukocyte count with coronary heart disease: meta‐analyses of prospective studies. JAMA 1998; 279: 1477–82
   PubMed Web of Science ®Google Scholar
• Thogersen A. M., Jansson J. H., Boman K., Nilsson T. K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241–7
   PubMed Web of Science ®Google Scholar
• Kohler H. P., Grant P. J. Plasminogen‐activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–801
   PubMed Web of Science ®Google Scholar
• Anand S., Yi Q., Gerstein H., Lonn E., Jacobs R., Vuksan V., Davis B., , for the Study of Health Assessment and Risk in Ethnic Groups (SHARE) and Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE‐AP) Investigators, et al. Relation of the Metabolic Syndrome and Fibrinolytic Disfunction to Cardiovascular Disease. Circulation 2003; 108: 420–5
   PubMed Web of Science ®Google Scholar
• Folsom A. R. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86: 366–73
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Brown N. J., Vaughan D. E., Harrison D. G., Metha J. L. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109((suppl IV))6–19
   Google Scholar
• Brunzell J. D., Sniderman A. D., Albers J. J., Kwiterovich P. O., Jr. Apoproteins B and A‐I and coronary artery disease in humans. Arteriosclerosis 1984; 4: 79–83
   PubMedGoogle Scholar
• Dunder K., Lind L., Zethelius B., Berglund L., Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle‐aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). Am Heart J 2004; 148: 596–601
   PubMed Web of Science ®Google Scholar
• Lamarche B., Moorjani S., Lupien P. J., Cantin B., Bernard P. M., Dagenais G. R., et al. Apolipoprotein A‐I and B levels and the risk of ischemic heart disease during five‐year follow‐up of men in the Quebec Cardiovascular Study. Circulation 1996; 94: 273–8
   PubMed Web of Science ®Google Scholar
• Stocker R., Keaney J. F., Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381–478
   PubMed Web of Science ®Google Scholar
• Austin M. A., Breslow J. L., Hennekens C. H., Buring J. E., Willett W. C., Krauss R. M. Low‐density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917–21
   PubMed Web of Science ®Google Scholar
• Toshima S., Hasegawa A., Kurabayashi M., Itabe H., Takano T., Sugano J., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2243–7
   PubMed Web of Science ®Google Scholar
• Bonadonna R., Bonora E. Glucose and free fatty acid metabolism in human obesity. Relationship with insulin resistance. Diabetes Rev 1997; 5: 21–51
   Google Scholar
• Steinberg H. O., Baron A. D. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623–34
   PubMed Web of Science ®Google Scholar
• Jouven X., Charles M. A., Desnos M., Ducimetière P. Circulating nonesterified fatty acid level as predictive risk factor for sudden death in the population. Circulation 2001; 104: 756–61
   PubMed Web of Science ®Google Scholar
• Saggiani F., Pilati S., Targher G., Branzi P., Muggeo M., Bonora E. Serum uric acid and related factors in 500 hospitalized subjects. Metabolism 1996; 45: 1557–61
   PubMed Web of Science ®Google Scholar
• Culleton B. F., Larson M. G., Kannel W. B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med 1999; 131: 7–13
   PubMed Web of Science ®Google Scholar
• Fang J., Alderman M. H. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow‐up study, 1971–1992. JAMA 2000; 283: 2404–10
   PubMed Web of Science ®Google Scholar
• Niskanen L. K., Laaksonen D. E., Nyyssonen K., Alfthan G., Lakka H. M., Lakka T. A., et al. Uric acid level as a risk factor for cardiovascular and all‐cause mortality in middle‐aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546–51
   PubMed Web of Science ®Google Scholar
• Schlotte V., Sevanian A., Hochstein P., Weithmann K. U. Effect of uric acid and chemical analogues on oxidation of human low density lipoprotein in vitro. Free Radic Biol Med 1998; 25: 839–47
   PubMed Web of Science ®Google Scholar
• Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39–42
   PubMed Web of Science ®Google Scholar
• Lusis A. J. Atherosclerosis. Nature 2000; 407: 233–41
   PubMed Web of Science ®Google Scholar
• Libby P., Ridker P. M., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43
   PubMed Web of Science ®Google Scholar
• Schulze M. B., Rimm E. B., Li T., Rifai N., Stampfer M. J., Hu F. B. C‐reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004; 27: 889–94
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Buring J. E., Rifai N. C‐reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Buring J., Shih J., Matias M., Hennekens C. H. Prospective study of C‐reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731–3
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Rifai N., Rose L., Buring J. E., Cook N. R. Comparison of C‐reactive protein and low‐density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–65
   PubMed Web of Science ®Google Scholar
• Brown D. W., Giles W. H., Croft J. B. White blood cell counts an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001; 54: 316–22
   PubMed Web of Science ®Google Scholar
• Erikssen G., Liestol K., Bjornholt J. V., Stormorken H., Thaulow E., Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J 2000; 21: 1614–20
   PubMed Web of Science ®Google Scholar
• Kiechl S., Willeit J., Egger G., Poewe W., Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck Study. Circulation 1997; 96: 3300–7
   PubMed Web of Science ®Google Scholar
• Kiechl S., Egger G., Mayr M., Wiedermann C. J., Bonora E., Oberhollenzer F., et al. Chronic infections and the risk of carotid atherosclerosis. Prospective results from a large population study. Circulation 2001; 103: 1064–70
   PubMed Web of Science ®Google Scholar
• Kiechl S., Lorenz E., Reindl M., Wiedermann C. J., Oberhollenzer F., Bonora E., et al. Toll‐like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185–92
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor‐alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–53
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Rifai N., Stampfer M. J., Hennekens C. H. Plasma concentration of interleukin‐6 and the risk of future mycardial infarction among apparently healthy men. Circulation 2000; 101: 1767–72
   PubMed Web of Science ®Google Scholar
• Cinnes D. B., Pollak E. S., Buck C. A., Loscalzo J., Zimmermann G. A., McEver R. P., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527–61
   Google Scholar
• Gearing A. J. H., Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506–12
   PubMedGoogle Scholar
• Hwang S. J., Ballantyne C. M., Sharrett A. R., Smith L. C., Davis C. E., Gotto A. M., et al. Circulating adhesion molecules VCAM‐1, ICAM‐1, and E‐selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 4219–25
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Roitman‐Johnson B., Stampfer M. J., Allen J. Plasma concentration of soluble intercellular adhesion molecole‐1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Buring J. E., Rifai N. Soluble P‐selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491–5
   PubMed Web of Science ®Google Scholar
• Malik I., Danesh J., Whincup P., Bhatia V., Papacosta O., Walker M., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta‐analysis. Lancet 2001; 358: 971–5
   PubMed Web of Science ®Google Scholar
• Ahima R. S., Flier J. S. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 1999; 11: 327–32
   Google Scholar
• Chandran M., Phillips S. A., Ciaraldi T., Henry R. P. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003; 26: 2442–50
   PubMed Web of Science ®Google Scholar
• Berg A. H., Scherer P. E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939–49
   PubMed Web of Science ®Google Scholar
• Bodary P. F., Gu S., Shen Y., Hasty A. H., Buckler J. M., Eitzman D. T. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E‐deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 1634–42
   Google Scholar
• Shin H. J., Oh J., Kang S. M., Lee J. H., Shin M. J., Hwang K. C., et al. Leptin induces hypertrophy via p38 mitogen‐activated protein kinase in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2005; 329: 18–24
   Google Scholar
• Pischon T., Girman C. J., Hotamisligil G. S., Rifai N., Hu F. B., Rimm E. B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–7
   PubMed Web of Science ®Google Scholar
• Wallace A. M., McMahon A. D., Packard C. J., Kelly A., Sheperd J., Gaw A., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052–6
   PubMed Web of Science ®Google Scholar
• Ford E. S., Giles W., Dietz W. H. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356–9
   PubMed Web of Science ®Google Scholar
• Balkau B., Charles M. A., Drivsholm T., Borch‐Johnsen K., Wareham N., Yudkin J. S., et al. European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and al alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364–76
   PubMed Web of Science ®Google Scholar
• Meigs J. B., Wilson P. W. F., Nathan D. M., D'Agostino R. B., Sr, Williams K., Haffner S. M. Prevalence and characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 2160–7
   PubMed Web of Science ®Google Scholar
• Palaniappan L., Carnethon M. R., Wang Y., Hanley A. J. G., Fortmann S. P., Haffner S. M., et al. Predictors of the incident Metabolic Syndrome in adults. The Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27: 788–93
   PubMed Web of Science ®Google Scholar
• Modkad A. H., Serdula M. K., Dietz W. H., Bowman B. A., Marks J. S., Koplan J. P. The spread of obesity epidemic in the United States. 1991–1998. JAMA 1999; 282: 1519–22
   Google Scholar
• Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–53
   PubMed Web of Science ®Google Scholar
• Eckel R. H., Grundy S. M., Zimmet P. Z. The metabolic syndrome. Lancet 2005; 365: 1415–28
   PubMed Web of Science ®Google Scholar
• Carr D. B., Utzschneider K. M., Hull R. L., Kodama K., Retzlaff B. M., Brunzell J. D., et al. Intra‐abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087–94
   PubMed Web of Science ®Google Scholar
• Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with metabolic syndrome. Diabetes care 2001; 24: 683–9
   PubMed Web of Science ®Google Scholar
• Lakka H. M., Laaksonen D. E., Lakka T. A., Niskanen L. K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle‐aged men. JAMA 2002; 288: 2709–16
   PubMed Web of Science ®Google Scholar
• Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R., et al. Carotid atheroclerosis and coronary heart disease in the Metabolic Syndrome. Prospective data from the Bruneck Study. Diabetes Care 2003; 26: 1251–7
   PubMed Web of Science ®Google Scholar
• Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D. St. J., Haffner S. M., et al. Metabolic syndrome with and without C‐reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 2003; 108: 414–9
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Buring J. E., Cook N. R., Rifai N. C‐reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8‐year follow‐up of 14719 initially healthy American women. Circulation 2003; 107: 391–7
   PubMed Web of Science ®Google Scholar
• Bonora E., Targher G., Formentini G., Calcaterra F., Lombardi S., Marini F., et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21: 52–8
   PubMed Web of Science ®Google Scholar
• Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch‐Johnsen K., Pyorala K., for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all‐cause and cardiovascular mortality in nondiabetic european men and women. Arch Intern Med 2004; 164: 1066–76
   PubMed Web of Science ®Google Scholar
• Hunt K. J., Resendez R. G., Williams K., Haffner S. M., Stern M. P. National cholesterol education program versus World Health Organization metabolic syndrome in relation to all‐cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–7
   PubMed Web of Science ®Google Scholar
• Malik S., Wong N. D., Franklin S. S., Kamath T. V., L'Italien G. J., Pio J. R., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–50
   PubMed Web of Science ®Google Scholar
• Girman C. J., Rhodes T., Mercuri M., Pyorala K., Kjekshus J., Pedersen T. R., et al. 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136–41
   PubMed Web of Science ®Google Scholar
• McNeill A., Rosamond W. D., Girman C. J., Hill Golden S., Schmidt M. I., East H. E., et al. The metabolic syndrome and 11‐year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 385–90
   PubMed Web of Science ®Google Scholar
• Rutter M. K., Meigs J. B., Sullivan L. M., D'Agostino R. B., Wilson P. W. F. C‐reactive protein, the Metabolic Syndrome and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380–5
   PubMed Web of Science ®Google Scholar
• Scuteri A., Najjar S. S., Morrell C. H., Lakatta E. G. Cardiovascular Health Study. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005; 28: 882–7
   PubMed Web of Science ®Google Scholar
• Dekker J. M., Girman C., Rhodes T., Nijpels G., Stehouwer C. D., Bouter L. M., et al. Metabolic syndrome and 10‐year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–73
   PubMed Web of Science ®Google Scholar
• Balkau B., Charles M. A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442–3
   PubMed Web of Science ®Google Scholar
• Einhorn D., Reaven G. M., Cobin R. H. American College of Endocrinology position statement on the Insulin Resistance Syndrome. Endocr Pract 2002; 9: 236–52
   Google Scholar
• Lempiainen P., Mykkanen L., Pyorala K., Laakso M., Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100: 123–8
   PubMed Web of Science ®Google Scholar
• Pyorala M., Miettinen H., Halonen P., Laakso M., Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle‐aged men. The 22 follow‐up results of the Helsinki Policemen Study. Arterioscl Thromb Vasc Biol 2000; 20: 538–44
   PubMed Web of Science ®Google Scholar
• Kuusisto J., Lempiainen P., Mykkanen L., Laakso M. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 2001; 24: 1629–33
   PubMed Web of Science ®Google Scholar
• Kahn R., Buse J., Ferrannini E., Stern M. The Metabolic Syndrome: time for a critical appraisal. Diabetes Care 2005; 28: 2289–304
   PubMed Web of Science ®Google Scholar
• O'Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian Aborigens after temporary reversion to traditional lifestyle. Diabetes 1984; 33: 596–603
   PubMed Web of Science ®Google Scholar
• Ziccardi P., Nappo F., Giugliano G., Esposito K., Marfella R., Cioffi M., et al. Reduction of inflammatory cytokine concentration and improvement of endothelial functions in obese women after weight loss for one year. Circulation 2002; 105: 804–9
   PubMed Web of Science ®Google Scholar
• Kopp H. P., Kopp C. W., Festa A., Kryzanowska K., Kriwanek S., Minar E., et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042–7
   PubMed Web of Science ®Google Scholar
• Reaven G., Segal K., Hauptman J., Boldrin M., Lucas C. Effect of orlistat‐assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87: 827–31
   PubMed Web of Science ®Google Scholar
• Landin K., Tengborn L., Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181–7
   PubMed Web of Science ®Google Scholar
• Grant P. J. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29((4 Pt 2))6S44–52
   Google Scholar
• Nagi D. K., Yudkin J. S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621–9
   PubMed Web of Science ®Google Scholar
• Yu J. G., Javorschi S., Hevener A. L., Kruszynska Y. T., Norman R. A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968–74
   PubMed Web of Science ®Google Scholar
• Haffner S. M., Greenberg A. S., Weston W. M., Chen H., Williams K., Freed M. I. Effects of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679–84
   PubMed Web of Science ®Google Scholar
• Raji A., Seely E. W., Bekins S. A., Williams G. H., Simonson D. C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172–8
   PubMed Web of Science ®Google Scholar
• Rosenblatt S., Miskin B., Glazer N. B., Prince M. J., Robertson K. E. Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413–23
   PubMed Web of Science ®Google Scholar
• Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493–9
   PubMed Web of Science ®Google Scholar
• Parulkar A. A., Pendergrass M. L., Granda‐Ayala R., Lee T. R., Fonseca V. A. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61–71
   PubMed Web of Science ®Google Scholar